Covidien is planning to spin off its pharmaceuticals business into a standalone public company. The unit supplies generators used to produce technetium-99m, a medical isotope, and offers an integrated system of diagnostic contrast media in prefilled syringes and injectors.
Positron has installed its PosiRx Beta system at the University of New Mexico in Albuquerque, and the system completed testing of key criteria required for validation.
Written by Justine Cadet
The current crisis of the Japanese nuclear reactors as a result of the natural disasters should have “a fairly small impact on the U.S. attempts to develop medical isotopes domestically,” Robert W. Atcher, PhD, MBA, leader of the medical isotope task force and past-president of the Society of Nuclear Medicine (SNM), explained in an interview.
The FDA has approved Covidien’s production of technetium-99m (Tc-99m) derived from the low-enriched uranium molybdenum-99 (Mo-99) isotope.
RSS 
